NCT06493552View on ClinicalTrials.gov

Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

700

Participants

Timeline

Start Date

March 15, 2025

Primary Completion Date

September 30, 2029

Study Completion Date

August 31, 2034

Conditions
Muscle-Invasive Bladder CarcinomaMetastatic Urothelial Carcinoma
Interventions
DRUG

SEphB4-HSA

A recombinant protein comprised of the soluble form of human receptor EphB4 fused to human serum albumin.

DRUG

Pembrolizumab

Antibody to human PD-1.

DRUG

Gemcitabine

A chemotherapy drug used to treat various types of cancer.

DRUG

Cisplatin

A type of chemotherapy drug called an alkylating agent used to treat various types of cancer.

DRUG

Enfortumab vedotin

Nectin-4-directed antibody and microtubule inhibitor conjugate.

Trial Locations (1)

90403

RECRUITING

Sarcoma Oncology Center, Santa Monica

All Listed Sponsors
lead

Vasgene Therapeutics, Inc

INDUSTRY